cm93

CM93 is an orally bioavailable, blood-brain-barrier penetrant, third-generation covalent small molecule inhibitor of the epidermal growth factor receptor (EGFR) and its mutant forms, including EGFR variant III (EGFRvIII). It acts as a potent and irreversible tyrosine kinase inhibitor targeting both wild-type and mutant EGFR. CM93 is designed to overcome resistance mechanisms seen with earlier generation EGFR inhibitors and has demonstrated activity in preclinical models of glioblastoma. The drug is not a substrate for p-glycoprotein or breast cancer resistance protein (BCRP), which may enhance its brain penetration. Its primary indication under investigation is recurrent glioblastoma characterized by EGFR mutation or amplification. The developer of CM93 is Crimson BioPharm[1][2][3][4].